An ultra-modern research hub and training centre located in the heart of the Université de Montréal, the Institute for Research in Immunology and Cancer (IRIC) was founded in 2003 to shed light on the mechanisms of cancer and discover new effective therapies.
It operates according to a unique model in Canada, focused on results that encompass an anti-cancer drug discovery chain, state-of-the-art research labs and facilities, and a new collaborative approach leveraging multiple types of expertise in Canada and around the world.
To accelerate the translation of discoveries into innovation, IRIC has created IRICoR, a centre responsible for stepping up discovery, development, valorization, and commercialization of innovative drugs and therapies. IRIC’s flexible business model allows it to develop optimal value for its projects through strategic partnerships or the creation of spin-off companies. In less than eight years, IRIC’s discoveries resulted in therapies that have entered clinical trials.
According to projections found in the report Canadian Cancer Statistics 2015, a 40 percent increase in cancer diagnostics is expected over the next 15 years. Research is a fundamental priority in the fight against cancer. “Because of its renowned researchers’ expertise, its commitment to training today’s young scientists into tomorrow’s leading researchers, and its distinctive research model, the Institute is at the forefront of the fight against cancer,” says Michel Bouvier, IRIC’s Chief Executive Officer.
“Our innovating approach to research has already led to dramatic breakthroughs that will, over the coming years, have a significant impact and change the lives of those affected by cancer.”